Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharmexa Pancreatic Cancer Vaccine Fails Phase III Study

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm says it will continue enrolling another Phase III trial, with data expected in 2011.

You may also be interested in...

Antigenics’ Oncophage Approved In Russia, First Therapeutic Cancer Vaccine To Enter Marketplace

The biologic will launch this summer at a price in the lower range of $50,000-$100,000/patient/year, the typical cost of new cancer drugs in Russia, firm tells “The Pink Sheet” DAILY.

Dendreon Catches A Break For Provenge

Amended FDA agreement hastens IMPACT final analysis by one year.

Failed MyVax Cancer Vaccine Trial Could Be Due To Active Comparator, Genitope Says

Firm remains optimistic about the non-Hodgkin’s lymphoma vaccine due to a statistically significant increase in progression-free survival among MyVax responders.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts